Biotech Pharmaceutical Corp

Biotech Pharmaceutical Co., Ltd. (BPC) is a high-tech Sino-Cuban joint venture established in 2000, focusing on the research, development, and manufacturing of therapeutic monoclonal antibodies and recombinant proteins. The company is best known for its flagship product, Nimotuzumab (Taixinsheng), which was the first humanized monoclonal antibody approved in China for the treatment of nasopharyngeal carcinoma. BPC operates large-scale mammalian cell culture facilities and maintains a robust pipeline targeting various oncology and autoimmune indications. Headquartered in Beijing, the company leverages advanced biotechnology from Cuba's Center of Molecular Immunology (CIM) to serve the Chinese and international markets.